Skip to main content

HomeResearchIGF-1

PerformanceMedium RiskResearch Only

IGF-1

Insulin-like Growth Factor 1 · Somatomedin C · native IGF-1

CategoryPerformance
Half-life
Routesubcutaneous, intramuscular
RiskMedium Risk
Providers6 listed

About IGF-1

Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake. Much shorter half-life (~15 min) than the LR3 analog (~20-30 hr) due to binding protein interactions.

The native form of insulin-like growth factor 1, produced primarily by the liver in response to growth hormone stimulation. The primary mediator of GH effects on muscle growth, fat metabolism, and tissue repair. Distinct from IGF-1 LR3 (the extended long-acting analog already in catalog).

Research Areas

muscle growthrecoveryfat metabolismtissue repair

Regulatory & Evidence

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.

Regulatory Status

Availability Status
Research Only

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find IGF-1

6 providers

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.